{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:22Z","timestamp":1787113642978,"version":"build-2736575974"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116878","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:54:57Z","timestamp":1782431697000},"page":"116878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS)"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8491-026X","authenticated-orcid":false,"given":"Th\u00e9o","family":"Erard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Amini-Adle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-6009","authenticated-orcid":false,"given":"Julie","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Puyraveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Jeudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouidad","family":"Zehou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Celerier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Lesage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Khammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-5990","authenticated-orcid":false,"given":"Charl\u00e9e","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116878_bib1","unstructured":"Bernard G., Alain D., Marc P., G\u00e9raldine J., Elif H., Thomas J., et al. Actualisation des donn\u00e9es concernant le m\u00e9lanome stade III: nouvelles recommandations du Groupe de Canc\u00e9rologie Cutan\u00e9e."},{"issue":"18","key":"10.1016\/j.ejca.2026.116878_bib2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final results for adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"391","author":"Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2026.116878_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116878_bib4","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"Eggermont","year":"2024","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"19","key":"10.1016\/j.ejca.2026.116878_bib5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2026.116878_bib6","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus Ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2026.116878_bib7","first-page":"1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"9","key":"10.1016\/j.ejca.2026.116878_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/jnci\/djad081","article-title":"Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study","volume":"115","author":"Helgadottir","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2026.116878_bib9","article-title":"Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era","volume":"9","author":"Hagopian","year":"2024","journal-title":"ESMO Open F\u00e9vr"},{"issue":"5","key":"10.1016\/j.ejca.2026.116878_bib10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jdv.18779","article-title":"Real-world outcomes using PD-1 antibodies and BRAF +\u2009MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland","volume":"37","author":"Schumann","year":"2023","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"10.1016\/j.ejca.2026.116878_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-02776","article-title":"Long-term follow-up of real-world adjuvant anti-PD\u22121 checkpoint inhibition and targeted therapy in stage III melanoma patients","author":"Lodde","year":"2025","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116878_bib12","first-page":"41","article-title":"Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study","volume":"16","author":"Li","year":"2022","journal-title":"Pharm Basel Switz"},{"issue":"6","key":"10.1016\/j.ejca.2026.116878_bib13","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin Nov"},{"key":"10.1016\/j.ejca.2026.116878_bib14","first-page":"256","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990 juill"},{"key":"10.1016\/j.ejca.2026.116878_bib15","article-title":"Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study","volume":"71","author":"Bai","year":"2024","journal-title":"EClinicalMedicine mai"},{"issue":"2","key":"10.1016\/j.ejca.2026.116878_bib16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3390\/cancers15020409","article-title":"Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis","volume":"15","author":"De Meza","year":"2023","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejca.2026.116878_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7257","article-title":"Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies","volume":"13","author":"Dima","year":"2024","journal-title":"Cancer Med"},{"issue":"17","key":"10.1016\/j.ejca.2026.116878_bib18","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers16173095","article-title":"Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD\u22121 Agents in Stage III\/IV Resected Melanoma","volume":"16","author":"Roccuzzo","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.ejca.2026.116878_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2026.116878_bib20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:14:28Z","timestamp":1787112868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["S0959804926006593"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116878","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116201","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116878"}}